MERRIMACK PHARMACEUTICALS INC Form DEFA14A April 19, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant X

Filed by a Party other than the Registrant O

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o

Filing Party:

Date Filed:

Definitive Proxy Statement o **Definitive Additional Materials** \mathbf{X} Soliciting Material under §240.14a-12 0

> MERRIMACK PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

(3)

(4)

	`			
Payment of Filin	ng Fee (Check the appro	priate box):		
X	No fee required.			
0	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.			
	(1)	Title of each class of securities to which transaction applies:		
	(2)	Aggregate number of securities to which transaction applies:		
	(3)	Per unit price or other underlying value of transaction computed pursuar to Exchange Act Rule 0-11 (set forth the amount on which the filing fee calculated and state how it was determined):		
	(4)	Proposed maximum aggregate value of transaction:		
	(5)	Total fee paid:		
0 0	Check box if any part	<u> </u>		
	(2)	Form, Schedule or Registration Statement No.:		